Canthaxanthin

OTHER NAME(S): 4,4-Diketo-Beta-Carotene, Beta,Beta-Carotene-4,4-Dione, Cantaxantine, Carophyll Red, CI Food Orange 8, Colour Index No. 40850, E161, Roxanthin Red 10, Canthaxanthin, Cantaxantina, Canthaxanthine

Overview

Canthaxanthin is a dye that is similar to the chemical that makes carrots orange. It occurs naturally and can also be made in a laboratory. People use it as medicine.

Canthaxanthin is used to reduce sensitivity to sunlight (photosensitivity) experienced by people who have a rare genetic disease called erythropoietic protoporphyria (EPP). In these people, sunlight can cause skin reactions such as rash, itch, and eczema. Canthaxanthin is also used to reduce sun sensitivity caused by certain medications and other conditions, but there is no good scientific evidence to support these uses.

Canthaxanthin is a dye similar to the carotenes in vegetables such as carrots. It deposits in the skin to produce an artificial "tan." It might protect against sun sensitivity through antioxidant activity.

Orobronze (canthaxanthin) is sold in Canada as a nonprescription "tanning pill." In the U.S., the Food and Drug Administration (FDA) has not approved tanning pills containing canthaxanthin. Nevertheless, these products seem to be readily available to people in the U.S. through mail order and tanning salons.

In foods, canthaxanthin is used as food coloring and is added to animal feed to improve the color of chicken skins, egg yolks, salmon, and trout.

In manufacturing, canthaxanthin is used in cosmetics and in medications.

Canthaxanthin is a dye similar to the carotenes in vegetables such as carrots. It deposits in the skin to produce an artificial "tan." It might protect against sun sensitivity through antioxidant activity.

References
  1. Mathews-Roth MM. Carotenoids in erythropoietic protoporphyria and other photosensitivity diseases. Ann N Y Acad Sci, 1993; 691:127-38.
  2. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  3. Anon. FDA Import Alert #53-03, 1991. Availble at: https://www.fda.gov/ora/fiars/ora_import_ia5303.html
  4. Pine, D. Cool tips for a hot season. FDA/CFSAN Cosmetics 1992. Available at: https://vm.cfsan.fda.gov/~dms/cos-815.html
  5. Electronic Code of Federal Regulations. Title 21. Part 73 - Listing of Color Additives Exempt from Certification. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=73.75
  6. Jackson R. Quick suntan pills in Canada. J Am Acad Dermatol 1981;4:233.
  7. Lober CW. Canthaxanthin- the "tanning" pill. J Am Acad Dermatol 1985;13:660.
  8. Anon. A suntan in capsules - orobronze. Drug Ther Bull 1983;21:57.
  9. Rock GA, Decary F, Cole RS. Orange plasma from tanning capsules. Lancet 1981;1:1419-20.
  10. Bluhm R, Branch R, Johnston P, Stein R. Aplastic anemia associated with canthaxanthin ingested for 'tanning' purposes. JAMA 1990;264:1141-2.
  11. Harnois C, Samson J, Malenfant M, Rousseau A. Canthaxanthin retinopathy. Anatomic and funtional reversibility. Arch Ophthalmol 1989;107:538-40.
  12. Herbert V. Canthaxanthin toxicity. Am J Clin Nutr 1991;53:573-4.
  13. White GL Jr, Beesley R, Thiese SM, Murdock RT. Retinal crystals and oral tanning agents. Am Fam Physician 1988;37:125-6.
  14. Chang TS, Aylward W, Clarkson JG, Gass JD. Asymmetric canthaxanthin retinopathy. Am J Ophthalmol 1995;119:801-2.
  15. Leyon H, Ros AM, Nyberg S, Algvere P. Reversibility of canthaxanthin deposits within the retina. Acta Ophthalmol (Copenh) 1990;68:607-11.
  16. Espaillat A, Aiello LP, Arrigg PG, et al. Canthaxanthine retinopathy. Arch Ophthalmol 1999;117:412-3..
  17. Anon. Permitted colouring agents for use in medicinal products - E 161 Canthaxanthine. Health and Consumer Protection - The European Commission 1998. Available at: https://europa.eu.int/comm/food/index_en.htm
  18. Anon. Porphyria information for patients and their families. University of Cape Town / Medical Research Council - Liver Research Center 2000. Available at: https://web.uct.ac.za/depts/porphyria/
  19. Vainio H, Rautalahti M. An international evaluation of the cancer preventive potential of carotenoids. Cancer Epidemiol Biomarkers Prev 1998;7:725-8.
  20. Huang DS, Odeleye OE, Watson RR. Inhibitory effects of canthaxanthin on in vitro growth of murine tumor cells. Cancer Lett 1992;65:209-13.
  21. Stahl W, Sies H. The role of carotenoids and retinoids in gap junctional communication. Int J Vitam Nutr Res 1998;68:354-9.
  22. Camera, E., Mastrofrancesco, A., Fabbri, C., Daubrawa, F., Picardo, M., Sies, H., and Stahl, W. Astaxanthin, canthaxanthin and beta-carotene differently affect UVA-induced oxidative damage and expression of oxidative stress-responsive enzymes. Exp Dermatol 2009;18(3):222-231.
  23. Di Mascio, P., Devasagayam, T. P., Kaiser, S., and Sies, H. Carotenoids, tocopherols and thiols as biological singlet molecular oxygen quenchers. Biochem Soc Trans 1990;18(6):1054-1056.
  24. Thomsen, K., Schmidt, H., and Fischer, A. Beta-carotene in erythropoietic protoporphyria: 5 years' experience. Dermatologica 1979;159(1):82-86.
  25. Haeger-Aronsen, B., Krook, G., and Abdulla, M. Oral carotenoids for photohypersensitivity in patients with erythrohepatic protoporphyria, polymorphous light eruptions and lupus erythematodes discoides. Int.J.Dermatol. 1979;18(1):73-82.
  26. Mathews-Roth, M. M. Treatment of erythropoietic protoporphyria with beta-carotene. Photodermatol. 1984;1(6):318-321.
  27. Suhonen, R. and Plosila, M. The effect of beta-carotene in combination with canthaxanthin, Ro 8-8427 (Phenoro), in treatment of polymorphous light eruptions. Dermatologica 1981;163(2):172-176.
  28. Carpenter, K. L., Hardwick, S. J., Albarani, V., and Mitchinson, M. J. Carotenoids inhibit DNA synthesis in human aortic smooth muscle cells. FEBS Lett. 3-19-1999;447(1):17-20.
  29. Teicher, V. B., Kucharski, N., Martin, H. D., van der Saag, P., Sies, H., and Stahl, W. Biological activities of Apo-canthaxanthinoic acids related to gap junctional communication. Arch.Biochem.Biophys. 5-1-1999;365(1):150-155.
  30. Yemelyanov, A. Y., Katz, N. B., and Bernstein, P. S. Ligand-binding characterization of xanthophyll carotenoids to solubilized membrane proteins derived from human retina. Exp.Eye Res 2001;72(4):381-392.
  31. Kotake-Nara, E., Kushiro, M., Zhang, H., Sugawara, T., Miyashita, K., and Nagao, A. Carotenoids affect proliferation of human prostate cancer cells. J Nutr. 2001;131(12):3303-3306.
  32. Muller, K., Carpenter, K. L., Challis, I. R., Skepper, J. N., and Arends, M. J. Carotenoids induce apoptosis in the T-lymphoblast cell line Jurkat E6.1. Free Radic.Res 2002;36(7):791-802.
  33. Ito, Y., Suzuki, K., Suzuki, S., Sasaki, R., Otani, M., and Aoki, K. Serum antioxidants and subsequent mortality rates of all causes or cancer among rural Japanese inhabitants. Int.J Vitam.Nutr.Res 2002;72(4):237-250.
  34. Ito, Y., Wakai, K., Suzuki, K., Tamakoshi, A., Seki, N., Ando, M., Nishino, Y., Kondo, T., Watanabe, Y., Ozasa, K., and Ohno, Y. Serum carotenoids and mortality from lung cancer: a case-control study nested in the Japan Collaborative Cohort (JACC) study. Cancer Sci. 2003;94(1):57-63.
  35. Santamaria, L. and Bianchi-Santamaria, A. Carotenoids in cancer chemoprevention and therapeutic interventions. J Nutr.Sci.Vitaminol.(Tokyo) 1992;Spec No:321-326.
  36. Weber, U., Goerz, G., Baseler, H., and Michaelis, L. [Canthaxanthin retinopathy. Follow-up of over 6 years]. Klin.Monatsbl.Augenheilkd. 1992;201(3):174-177.
  37. Sujak, A., Gabrielska, J., Milanowska, J., Mazurek, P., Strzalka, K., and Gruszecki, W. I. Studies on canthaxanthin in lipid membranes. Biochim.Biophys.Acta 6-15-2005;1712(1):17-28.
  38. ElAttar, T. M. and Lin, H. S. Effect of retinoids and carotenoids on prostaglandin formation by oral squamous carcinoma cells. Prostaglandins Leukot.Essent.Fatty Acids 1991;43(3):175-178.
  39. Santamaria, L. A. and Santamaria, A. B. Cancer chemoprevention by supplemental carotenoids and synergism with retinol in mastodynia treatment. Med Oncol.Tumor Pharmacother. 1990;7(2-3):153-167.
  40. Daicker, B., Schiedt, K., Adnet, J. J., and Bermond, P. Canthaxanthin retinopathy. An investigation by light and electron microscopy and physicochemical analysis. Graefes Arch.Clin.Exp.Ophthalmol. 1987;225(3):189-197.
  41. Lonn, L. I. Canthaxanthin retinopathy. Arch.Ophthalmol. 1987;105(11):1590-1591.
  42. Harnois, C., Cortin, P., Samson, J., Boudreault, G., Malenfant, M., and Rousseau, A. Static perimetry in canthaxanthin maculopathy. Arch.Ophthalmol. 1988;106(1):58-60.
  43. Santamaria, L., Benazzo, L., Benazzo, M., and Bianchi, A. First clinical case-report (1980-88) of cancer chemoprevention with beta-carotene plus canthaxanthin supplemented to patients after radical treatment. Boll.Chim.Farm. 1988;127(4):57S-61S.
  44. Eales, L. The effects of canthaxanthin on the photocutaneous manifestations of porphyria. S.Afr.Med.J. 12-16-1978;54(25):1050-1052.
  45. Gupta, A. K., Haberman, H. F., Pawlowski, D., Shulman, G., and Menon, I. A. Canthaxanthin. Int.J.Dermatol. 1985;24(8):528-532.
  46. Raab, W. P., Tronnier, H., and Wiskemann, A. Photoprotection and skin coloring by oral carotenoids. Dermatologica 1985;171(5):371-373.
  47. Rollman, O. and Vahlquist, A. Psoriasis and vitamin A. Plasma transport and skin content of retinol, dehydroretinol and carotenoids in adult patients versus healthy controls. Arch.Dermatol Res 1985;278(1):17-24.
  48. Bareford, D., Cumberbatch, M., and Derrick, Tovey L. Plasma discolouration due to sun-tanning aids. Vox Sang. 1984;46(3):180-182.
  49. Tronnier, H. [Protective effect of beta-carotene and canthaxanthin against UV reactions of the skin]. Z.Hautkr. 7-1-1984;59(13):859-870.
  50. Macdonald, K., Holti, G., and Marks, J. Is there a place for beta-carotene/canthaxanthin in photochemotherapy for psoriasis? Dermatologica 1984;169(1):41-46.
  51. Gunson, H. H., Merry, A. H., Britton, G., and Stratton, F. Detection of carotenoids in blood donors taking Orobronze: a cautionary note. Clin.Lab Haematol. 1984;6(3):287-292.
  52. Wiskemann, A. [Light protection and increase of UV tolerance]. Z.Hautkr. 11-1-1984;59(21):1454-1462.
  53. Acevedo, P. and Bertram, J. S. Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells. Carcinogenesis 1995;16(9):2215-2222.
  54. Bruderer, P., Shahabpour, M., Christoffersen, S., Andre, J., and Ledoux, M. Hydroa vacciniforme treated by a combination of beta-carotene and canthaxanthin. Dermatology 1995;190(4):343-345.
  55. Zhang, L. X., Acevedo, P., Guo, H., and Bertram, J. S. Upregulation of gap junctional communication and connexin43 gene expression by carotenoids in human dermal fibroblasts but not in human keratinocytes. Mol.Carcinog. 1995;12(1):50-58.
  56. Carpenter, K. L., van, der, V, Hird, R., Dennis, I. F., Ding, T., and Mitchinson, M. J. The carotenoids beta-carotene, canthaxanthin and zeaxanthin inhibit macrophage-mediated LDL oxidation. FEBS Lett. 1-20-1997;401(2-3):262-266.
  57. Tyurin, V. A., Carta, G., Tyurina, Y. Y., Banni, S., Day, B. W., Corongiu, F. P., and Kagan, V. E. Peroxidase-catalyzed oxidation of beta-carotene in HL-60 cells and in model systems: involvement of phenoxyl radicals. Lipids 1997;32(2):131-142.
  58. Meraji, S., Ziouzenkova, O., Resch, U., Khoschsorur, A., Tatzber, F., and Esterbauer, H. Enhanced plasma level of lipid peroxidation in Iranians could be improved by antioxidants supplementation. Eur.J Clin.Nutr. 1997;51(5):318-325.
  59. Paetau, I., Chen, H., Goh, N. M., and White, W. S. Interactions in the postprandial appearance of beta-carotene and canthaxanthin in plasma triacylglycerol-rich lipoproteins in humans. Am.J.Clin.Nutr. 1997;66(5):1133-1143.
  60. Onogi, N., Okuno, M., Matsushima-Nishiwaki, R., Fukutomi, Y., Moriwaki, H., Muto, Y., and Kojima, S. Antiproliferative effect of carotenoids on human colon cancer cells without conversion to retinoic acid. Nutr.Cancer 1998;32(1):20-24.
  61. Labrousse, A. L., Salmon-Ehr, V., Eschard, C., Kalis, B., Leonard, F., and Bernard, P. Recurrent painful hand crisis in a four-year-old girl, revealing an erythropoietic protoporphyria. Eur.J Dermatol 1998;8(7):515-516.
  62. Haxo, F. Carotenoids in the mushroom Cantharellus cinnabarinus. Botan.Gaz. 1950;112:228-232.
  63. Isler, O. and Schudel, P. Syntheses and labeling of carotenoids. Wiss.Veroff.Deut.Ges.Ernahr. 1963;9:54-103.
  64. Hueber A, Rosentreter A, Severin M. Canthaxanthin retinopathy: long-term observations. Ophthalmic Res. 2011;46(2):103-6.